TGFB1 and glioblastoma: In addition to bevacizumab, several tyrosine kinase inhibitors such as sunitinib, sorafenib, imatinib, and galunisertib (LY2157299) were investigated for their ability to inhibit PDGFR and TGF-β signaling pathways in the context of GBM.